ORIGINAL PAPER
Response to corticosteroid therapy is not related to serum and urine NGAL concentration in nephrotic children
Submission date: 2018-02-18
Final revision date: 2018-05-28
Acceptance date: 2018-05-30
Publication date: 2018-07-20
Pediatr Pol 2018;93(3):245-250
KEYWORDS
TOPICS
ABSTRACT
Aim of the study:
Response to corticosteroids is a major factor determining the final outcome of nephrotic syndrome (NS) in children. There is no consensus in terms of specific biomarkers of steroid sensitivity. There are reports on the value of urine neutrophil gelatinase-associated lipocalin (uNGAL) as a marker of steroid sensitivity, although this has not been definitively established. Objectives: To evaluate serum (s) and urine (u) NGAL concentrations as markers of response to steroid therapy.
Material and methods:
This was a retrospective study including 43 patients (1-17 years old) divided into two groups as follows: 1) children with steroid-resistant nephrotic syndrome (SRNS, n = 14) treated with additional immunosuppressive drugs, including cyclosporine A (CsA) and/or mycophenolate mofetil (MMF); and 2) steroid-sensitive nephrotic syndrome (SSNS, n = 29). The control group consisted of age-matched healthy children (HC, n = 59).
Results:
Median sNGAL concentration was higher in nephrotic patients (83.0, 43.8-351 ng/ml) compared to HC (51.4, 12.1-193 ng/ml; p = 0.00). There was no difference in the sNGAL level between SRNS and SSNS patients (p = 0.34). Median uNGAL level was higher in the SRNS patients, compared to that in the SSNS group, although the difference was not significant (2.71 ng/ml, range: 0.02-62.8 ng/ml and 1.17 ng/ml, range: 0.02-99.3 ng/ml, respectively; p = 0.26). Median sNGAL was higher in children treated with triple-drug regimens including cyclosporine A (CsA) (82.6, 68.6-351 ng/ml) compared to the patients on double-drug regimen including mycophenolate mofetil (MMF) (p = 0.03). There was no correlation between sNGAL and CsA dose/blood concentration ratio. We found a negative correlation between sNGAL and renal function, reflected by the eGFR (r = –0.41, p = 0.01).
Conclusions:
sNGAL concentration did not differ between steroid-resistant and steroid-sensitive nephrotic syndrome patients. The higher sNGAL concentration in patients on triple therapy (cyclosporine A + mycophenolate mofetil + prednisone – CsA + MMF + PRED) reflects inferior renal function in patients with the most severe clinical course of NS.
Response to corticosteroids is a major factor determining the final outcome of nephrotic syndrome (NS) in children. There is no consensus in terms of specific biomarkers of steroid sensitivity. There are reports on the value of urine neutrophil gelatinase-associated lipocalin (uNGAL) as a marker of steroid sensitivity, although this has not been definitively established. Objectives: To evaluate serum (s) and urine (u) NGAL concentrations as markers of response to steroid therapy.
Material and methods:
This was a retrospective study including 43 patients (1-17 years old) divided into two groups as follows: 1) children with steroid-resistant nephrotic syndrome (SRNS, n = 14) treated with additional immunosuppressive drugs, including cyclosporine A (CsA) and/or mycophenolate mofetil (MMF); and 2) steroid-sensitive nephrotic syndrome (SSNS, n = 29). The control group consisted of age-matched healthy children (HC, n = 59).
Results:
Median sNGAL concentration was higher in nephrotic patients (83.0, 43.8-351 ng/ml) compared to HC (51.4, 12.1-193 ng/ml; p = 0.00). There was no difference in the sNGAL level between SRNS and SSNS patients (p = 0.34). Median uNGAL level was higher in the SRNS patients, compared to that in the SSNS group, although the difference was not significant (2.71 ng/ml, range: 0.02-62.8 ng/ml and 1.17 ng/ml, range: 0.02-99.3 ng/ml, respectively; p = 0.26). Median sNGAL was higher in children treated with triple-drug regimens including cyclosporine A (CsA) (82.6, 68.6-351 ng/ml) compared to the patients on double-drug regimen including mycophenolate mofetil (MMF) (p = 0.03). There was no correlation between sNGAL and CsA dose/blood concentration ratio. We found a negative correlation between sNGAL and renal function, reflected by the eGFR (r = –0.41, p = 0.01).
Conclusions:
sNGAL concentration did not differ between steroid-resistant and steroid-sensitive nephrotic syndrome patients. The higher sNGAL concentration in patients on triple therapy (cyclosporine A + mycophenolate mofetil + prednisone – CsA + MMF + PRED) reflects inferior renal function in patients with the most severe clinical course of NS.
REFERENCES (20)
1.
Gheissari A, Rezaii Z, Merrikhi A, et al. Association of neutrophil gelatinase associated lipocalin and cystatin-C with kidney function in children with nephrotic syndrome. Int J Prev Med 2013; 4: 956-963.
2.
Wasilewska A, Zoch-Zwierz W, Taranta-Janusz K, et al. Neutrophil gelatinase-associated lipocalin (NGAL): a new marker of cyclosporine nephrotoxicity? Pediatr Nephrol 2010; 25: 889-897.
3.
Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney Int 2012; 2 (Suppl.): 139-274.
4.
Bennett MR. Biomarkers of therapeutic response in primary nephrotic syndrome: response. Pediatr Nephrol 2013; 28: 161-162.
5.
Bennett MR, Piyaphanee N, Czech K, et al. NGAL distinguishes steroid sensitivity in idiopathic nephrotic syndrome. Pediatr Nephrol 2012; 27: 807-812.
6.
Chehade H, Parvex P, Poncet A, et al. Urinary low-molecular-weight protein excretion in pediatric idiopathic nephrotic syndrome. Pediatr Nephrol 2013; 28: 2299-2306.
7.
Mucha K, Foroncewicz B, Pączek L. How to diagnose and follow patients with glomerulonephritis without kidney biopsy? Pol Arch Med Wewn 2016; 126: 471-473.
8.
Serwin NM, Wiśniewska M, Jesionowska A, et al. Serum levels of 12 renal function and injury markers in patients with glomerulonephritis. Pol Arch Med Wewn 2016; 26: 483-493.
9.
Trachtman H. Biomarkers of therapeutic response in primary nephrotic syndrome. Pediatr Nephrol 2013; 28: 159.
10.
Noto A, Cibecchini F, Fanos V, et al. NGAL and Metabolomics: The Single Biomarker to Reveal the Metabolome Alterations in Kidney Injury. Biomed Res Int 2013; 2013: 612032.
11.
Stejskal D, Karpisek M, Humenanska V, et al. Lipocalin-2: development, analytical characterization, and clinical testing of a new ELISA. Horm Metab Res 2008; 40: 381-385.
12.
Janas RM, Ochocińska A, Snitko R, et al. Neutrophil gelatinase-associated lipocalin in blood in children with inflammatory bowel disease. J Gastroenterol Hepatol 2014; 29: 1883-1889.
13.
Nickavar A, Safaeian B, Sadeghi-Bojd S, et al. Urine Neutrophil Gelatinase Associated Lipocalin to Creatinine Ratio: A Novel Index for Steroid Response in Idiopathic Nephrotic Syndrome. Indian J Pediatr 2016; 83: 18-21.
14.
Schwartz GJ, Muńoz A, Schneider MF, et al. New equations to estimate GFR in children with CKD. J Am Soc Nephrol 2009; 20: 629-637.
15.
Delanaye P, Rozet E, Krzesinski JM, et al. Urinary NGAL measurement: biological variation and ratio to creatinine Clin Chim Acta 2011; 412: 390.
16.
Waikar SS, Sabbisetti VS, Bonventre JV. Normalization of urinary biomarkers to creatinine during changes in glomerular filtration rate. Kidney Int 2010; 78: 486-494.
17.
Gacka E, Życzkowski M, Bogacki R, et al. The Usefulness of Determining Neutrophil Gelatinase-Associated Lipocalin Concentration Excreted in the Urine in the Evaluation of Cyclosporine A Nephrotoxicity in Children with Nephrotic Syndrome. Dis Markers 2016; 2016: 6872149.
18.
Korzeniecka-Kozerska A, Wasilewska A, Tenderenda E, et al. Urinary MMP-9/NGAL ratio as a potential marker of FSGS in nephrotic children. Dis Markers 2013; 34: 357-362.
19.
Bennett MR, Pleasant L, Haffner Ch, et al. Novel Biomarker Panel to Identify Steroid Resistance in Childhood Idiopathic Nephrotic Syndrome. Biomark Insights 2017; 12: 1-11.
20.
Lee JE, Lee YH, Kim SY, et al. Systematic biomarker discovery and coordinative validation for different primary nephrotic syndromes using gas chromatography-mass spectrometry. J Chromatogr A 2016; 1453: 105-115.
Share
RELATED ARTICLE
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
